MAIA Biotechnology (MAIA) Gains from Investment Securities (2021 - 2026)
MAIA Biotechnology (MAIA) posted quarterly Gains from Investment Securities of -$254955.0 for Q1 2026, up 69.13% year-over-year from -$150742.0 in Q1 2025, and down 0.57% quarter-over-quarter from -$253512.0 in Q4 2025.
MAIA Biotechnology (MAIA) Gains from Investment Securities (2021 - 2026) Analysis & Trends
MAIA Biotechnology (MAIA) has reported Gains from Investment Securities for 6 consecutive years, with -$254955.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Gains from Investment Securities rose 69.13% year-over-year to -$254955.0; the TTM figure through Mar 2026 stood at -$627176.0 (down 137.43% YoY), while the FY2025 annual figure was -$1.2 million, down 117.93% from the prior year.
- Gains from Investment Securities fell to -$254955.0 in Q1 2026 per MAIA's latest filing, from -$253512.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $5.2 million in Q2 2024 and bottomed at -$1.3 million in Q3 2024.
- Historically, Gains from Investment Securities has averaged $328404.6 across 5 years, with a median of -$102799.0 in 2023.
- On a YoY basis, Gains from Investment Securities climbed as much as 20066.09% in 2024 and fell as far as 7217.57% in 2024.
- MAIA Biotechnology's Gains from Investment Securities stood at $29636.0 in 2022, then tumbled by 313.24% to -$63196.0 in 2023, then plunged by 1996.25% to -$1.3 million in 2024, then soared by 80.86% to -$253512.0 in 2025, then declined by 0.57% to -$254955.0 in 2026.
- Business Quant data shows MAIA's Gains from Investment Securities at -$254955.0 in Q1 2026, -$253512.0 in Q4 2025, and -$379311.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | MAIA Biotechnology | 84.50 Mn | 56.91 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 69,829.00 |
| Jun 30, 2026 | 69,829.00 |
| Mar 31, 2026 | -254,955.00 |
| Mar 31, 2026 | -254,955.00 |
| Dec 31, 2025 | -253,512.00 |
| Dec 31, 2025 | -253,512.00 |
| Sep 30, 2025 | -379,311.00 |
| Sep 30, 2025 | -379,311.00 |
| Jun 30, 2025 | 260,602.00 |
| Jun 30, 2025 | 260,602.00 |
| Mar 31, 2025 | -825,989.00 |
| Mar 31, 2025 | -825,989.00 |
| Dec 31, 2024 | -1.32 Mn |
| Dec 31, 2024 | -1.32 Mn |
| Sep 30, 2024 | -1.33 Mn |
| Sep 30, 2024 | -1.33 Mn |
| Jun 30, 2024 | 5.16 Mn |
| Jun 30, 2024 | 5.16 Mn |
| Mar 31, 2024 | 4.18 Mn |
| Mar 31, 2024 | 4.18 Mn |